This site is intended for U.S. healthcare professionals.

Visit Pfizer Medical

Menu

Close

Sign InLog Out
ProductsOrderMaterialsCo-pay Cards & Patient Savings OffersRequest SamplesHospital ProductsVaccinesPatient AssistancePfizer Oncology TogetherPfizer RxPathwaysExplore ContentEventsMaterialsVideosContact
Search

Menu

Close

HomeClinical InformationClinical InformationACIP RecommendationsWhat is TicoVac®?What is TBE?Symptoms & Risk FactorsDemonstrated EffectivenessDosing & Administration ScheduleResourcesResourcesMaterialsVideosOrder TicoVac®
Prescribing Information Indication Patient Site
What is TBE?What is Tick-Borne Encephalitis Virus (TBEV) & How is it Transmitted?

The TBE virus is a rare, zoonotic arbovirus traditionally endemic to Central and Eastern Europe, as well as Russia, but has also been reported in Eastern Asian countries.1 The virus itself is a member of the Flavivirus family, which also includes viruses that can cause dengue fever, yellow fever, and Japanese encephalitis.2

Infection of TBE virus by ticks can occur in any place where ticks are endemic, such as wooded areas, parks, gardens, forests, or other outdoor locations.3

It Can Take Just One Bite.

When a tick acting as a TBE vector bites humans or animals, there is a significant risk that those organisms will become infected with the TBE virus.4

Transmission of the virus can also occur through the consumption of unpasteurized dairy products that have been contaminated with the TBE virus.4 TBE severity may be associated with viral subtype.1 TBE virus subtypes may cause different clinical characteristics of TBE and have different mortality rates.1,5

Infections from either of the subtypes have been shown to attack the Central Nervous Systems (CNS), leading to potentially severe or, on rare occasion, fatal outcomes.6

There is no cure or treatment for TBE.7,8 Patients infected are only able to manage their symptoms through various treatment methods.7,8​​​​​​​

References:Dumpis U, Crook D, Oksi J. Tick-borne encephalitis. Clin Infect Dis. 1999;28(4):882-890. doi: 10.1086/515195Bogovic P, Strle F. Tick-borne encephalitis: A review of epidemiology, clinical characteristics, and management. World J Clin Cases. 2015;3(5):430-441. doi:10.12998/wjcc.v3.i5.430World Health Organization. Tick-borne encephalitis. Accessed February 9, 2022. https://www.who.int/health-topics/tick-borne-encephalitis.European Centre for Disease Prevention and Control. Factsheet about tick-borne encephalitis (TBE). Accessed February 9, 2022. https://www.ecdc.europa.eu/en/tick-borne-encephalitis/facts/factsheet.Barp N, Trentini A, Di Nuzzo M, Mondardini V, Francavilla E, Contini C. Clinical and laboratory findings in tick-borne encephalitis virus infection. Parasite Epidemiol Control. 2020;10:e00160. doi:10.1016/j.parepi.2020.e00160Chrdle A, Chmelík V, Růžek D. Tick-borne encephalitis: What travelers should know when visiting an endemic country. Hum Vaccin Immunother. 2016;12(10):2694-2699. doi:10.1080/21645515.2016.1218098TicoVac® (Tick-Borne Encephalitis Vaccine). Prescribing Information. New York, NY: Pfizer Inc. 2021.Dobler G, Erber W, Bröker M, Schmitt HJ. The TBE Book. 4th ed. Global Health Press; 2021. ​​​​​​​Centers for Disease Control and Prevention. Tickborne Encephalitis. Travelers’ Health. Accessed February 9, 2022. https://wwwnc.cdc.gov/travel/diseases/tickborne-encephalitis.
SYMPTOMS & RISK FACTORS

Travelers spending time in wooded or grassy areas in many parts of Europe and Asia may be at risk for infection with tick-borne encephalitis virus (TBEV).9

​​​​​Go to symptoms & risk factors
Loading

To report an adverse event, please call 1-800-438-1985

Pfizer for Professionals 1-800-505-4426

This site is intended only for U.S. healthcare professionals. The products discussed in this site may have different product labeling in different countries. The information provided is for educational purposes only.

© 2024 Pfizer Inc. All rights reserved.

PP-TCV-USA-0190
INDICATION AND USAGE TicoVac® is a vaccine indicated for active immunization to prevent tick-borne encephalitis (TBE) and is approved for use in individuals 1 year of age and older.
IMPORTANT SAFETY INFORMATION
  • TicoVac® should not be given to anyone with a severe allergic reaction (e.g. anaphylaxis) to any component of TicoVac®.
  • Appropriate medical treatment and supervision must be available to manage possible anaphylactic reactions following administration of TicoVac®.
  • TicoVac® may not protect all individuals against TBE.
  • Some individuals with altered immunocompetence may have a reduced response to TicoVac®.
  • TicoVac® contains albumin, a derivative of human blood, and based on effective donor screening and product manufacturing processes carries an extremely remote and theoretical risk for transmission of viral diseases and variant Creutzfeldt-Jakob disease (vCJD).
  • In clinical studies, the most common adverse reactions in subjects 1 through 15 years of age who received TicoVac® were local tenderness (18.1%), local pain (11.2%), headache (11.1%), fever (9.6%), and restlessness (9.1%).
  • In clinical studies, the most common adverse reactions in subjects 16 through 65 years of age who received TicoVac® were local tenderness (29.9%), local pain (13.2%), fatigue (6.6%), headache (6.3%), and muscle pain (5.1%).
  • Safety and effectiveness have not been established in pregnant women.​​​
Patients should always ask their healthcare providers for medical advice about adverse events.You are encouraged to report negative side effects of vaccines to the US Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC). Visit http://www.vaers.hhs.gov or call 1-800-822-7967.
Please see full prescribing information for TicoVac® here.
Indication TicoVac® is a vaccine indicated for active immunization to prevent tick-borne encephalitis (TBE) and is approved for use in individuals 1 year of age and older.Important Safety Information
  • TicoVac® should not be given to anyone with a severe allergic reaction (e.g. anaphylaxis) to any component of TicoVac®.
  • Appropriate medical treatment and supervision must be available to manage possible anaphylactic reactions following administration of TicoVac®.
  • TicoVac® may not protect all individuals against TBE.
  • Some individuals with altered immunocompetence may have a reduced response to TicoVac®.
  • TicoVac® contains albumin, a derivative of human blood, and based on effective donor screening and product manufacturing processes carries an extremely remote and theoretical risk for transmission of viral diseases and variant Creutzfeldt-Jakob disease (vCJD).
  • In clinical studies, the most common adverse reactions in subjects 1 through 15 years of age who received TicoVac® were local tenderness (18.1%), local pain (11.2%), headache (11.1%), fever (9.6%), and restlessness (9.1%).
  • In clinical studies, the most common adverse reactions in subjects 16 through 65 years of age who received TicoVac® were local tenderness (29.9%), local pain (13.2%), fatigue (6.6%), headache (6.3%), and muscle pain (5.1%).
  • Safety and effectiveness have not been established in pregnant women.​​​
 Patients should always ask their healthcare providers for medical advice about adverse events. You are encouraged to report negative side effects of vaccines to the US Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC). Visit http://www.vaers.hhs.gov or call 1-800-822-7967. Please see full prescribing information for TicoVac® here. Indication
TicoVac® is a vaccine indicated for active immunization to prevent tick-borne encephalitis (TBE) and is approved for use in individuals 1 year of age and older.
You are now leaving PfizerPro  
You are now leaving a Pfizer operated website. Links to all outside sites are provided as a resource to our visitors. Pfizer accepts no responsibility for the content of sites that are not owned and operated by Pfizer. 
PP-MCL-USA-0367